AstraZeneca has now joined Pfizer in agreeing to sell its drugs to state Medicaid programs at “most-favored-nation” pricing ...
First deals impact Medicaid but drug makers hint they may sell all of their new drugs at most-favored-nation pricing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback